Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4405 ARTÍCULOS , VIENDO DEL 886 AL 900

Editorial: Molecular Diagnostics in the Detection of Neurodegenerative Disorders

Agrawal M, Cho WC.

Front Mol Biosci. 2017 Mar 2;4:10. doi: 10.3389/fmolb.2017.00010. eCollection 2017.

Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort

Kramberger MG, Auestad B, Garcia-Ptacek S, Abdelnour C, Olmo JG, Walker Z, Lemstra AW, Londos E, Blanc F, Bonanni L, McKeith I, Winblad B, de Jong FJ, Nobili F, Stefanova E, Petrova M, Falup-Pecurariu C, Rektorova I, Bostantjopoulou S, Biundo R, Weintraub D, Aarsland D; E-DLB.

J Alzheimers Dis. 2017;57(3):787-795. doi: 10.3233/JAD-161109.

Reliability and validity study of a Turkish version of the fatigue severity scale in Parkinson's disease patients

Ozturk EA, Gonenli Kocer B, Gundogdu I, Umay E, Cakci FA.

Int J Rehabil Res. 2017 Jun;40(2):185-190. doi: 10.1097/MRR.0000000000000224.

Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease

Christensen KV, Smith GP, Williamson DS.

Prog Med Chem. 2017;56:37-80. doi: 10.1016/bs.pmch.2016.11.002. Epub 2017 Jan 4.

Diagnostic accuracy of REM sleep behaviour disorder screening questionnaire: a meta-analysis

Li K, Li SH, Su W, Chen HB.

Neurol Sci. 2017 Jun;38(6):1039-1046. doi: 10.1007/s10072-017-2886-9. Epub 2017 Mar 17.

Sigma 1 Receptor and Ion Channel Dynamics in Cancer

Soriani O, Rapetti-Mauss R.

Adv Exp Med Biol. 2017;964:63-77. doi: 10.1007/978-3-319-50174-1_6.

Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection

Nguyen L, Lucke-Wold BP, Mookerjee S, Kaushal N, Matsumoto RR.

Adv Exp Med Biol. 2017;964:133-152. doi: 10.1007/978-3-319-50174-1_10.

The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma

Mysona B, Kansara N, Zhao J, Bollinger K.

Adv Exp Med Biol. 2017;964:299-307. doi: 10.1007/978-3-319-50174-1_20.

ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease

Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):317-324. doi: 10.1136/jnnp-2016-315277.

Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative

Ffytche DH, Pereira JB, Ballard C, Chaudhuri KR, Weintraub D, Aarsland D.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):325-331. doi: 10.1136/jnnp-2016-314832.

What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life

Marras C.

Mov Disord. 2017 Mar;32(3):364-365. doi: 10.1002/mds.26983.

Serum uric acid levels in patients with Parkinson's disease: A meta-analysis

Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, Yu WF, Jiao L.

PLoS One. 2017 Mar 20;12(3):e0173731. doi: 10.1371/journal.pone.0173731. eCollection 2017.

Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience

Nishijima H, Ueno T, Kon T, Haga R, Funamizu Y, Arai A, Suzuki C, Nunomura JI, Baba M, Tomiyama M.

J Neurol Sci. 2017 Apr 15;375:186-189. doi: 10.1016/j.jns.2017.01.066. Epub 2017 Jan 25.

"Was that a success or not a success?": a qualitative study of health professionals' perspectives on support for people with long-term conditions

Owens J, Entwistle VA, Cribb A, Skea ZC, Christmas S, Morgan H, Watt IS.

BMC Fam Pract. 2017 Mar 20;18(1):39. doi: 10.1186/s12875-017-0611-7.

Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat

Gonçalves D, Alves G, Fortuna A, Soares-da-Silva P, Falcão A.

Toxicol Appl Pharmacol. 2017 May 15;323:9-15. doi: 10.1016/j.taap.2017.03.013. Epub 2017 Mar 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias